Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) EBT Margin (2024)

Zentalis Pharmaceuticals has reported EBT Margin over the past 1 years, most recently at 177.47% for Q4 2024.

  • Quarterly results put EBT Margin at 177.47% for Q4 2024, changed N/A from a year ago — trailing twelve months through Sep 2025 was 556.56% (down 11503.0% YoY), and the annual figure for FY2024 was 245.74%, changed.
  • EBT Margin for Q4 2024 was 177.47% at Zentalis Pharmaceuticals, down from 25.11% in the prior quarter.
  • Over the last five years, EBT Margin for ZNTL hit a ceiling of 25.11% in Q1 2024 and a floor of 177.47% in Q4 2024.